Impel NeuroPharma has submitted a New Drug Application (NDA) to the U.S. FDA for its lead product candidate, INP104 (dihydroergotamine mesylate, or DHE) for review as a possible new treatment of acute migraine in adult patients. INP104 uses the Company’s proprietary Precision Olfactory Delivery (POD) technology – a novel delivery system that is the first to target the vascular-rich upper nasal space as a viable treatment pathway.   Impel is focused on the development and commercialization of t...